

DAFTAR PUSTAKA

- Abdulkareem, M.M., Abdulrahman, M.A., & Yassin, N.A. (2023). Molecular detection of plasmid-mediated quinolone resistance genes among clinical isolates of *Klebsiella pneumoniae* during Covid-19 pandemic. *PHAR* 70 (1) : 225–231.
- Akinjogunla, O.J., Odeyemi, A.T., Udofia, E.-A.S., Adefiranye, O.O., Yah, C.S., Ehinmore, I., *et al.* (2023). *Enterobacteriaceae* isolates from clinical and household tap water samples: antibiotic resistance, screening for extended-spectrum, metallo- and ampC-beta-lactamases, and detection of blaTEM, blaSHV and blaCTX-M in Uyo, Nigeria. *Germes* 13 (1) : 50–59.
- Anonim (2025). CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, 35th ed, 1. Clinical and Laboratory Standard Institute, Pennsylvania, hal. 1-396.
- Anonim (2024). Laporan Program Pengendalian Resistensi Antimikroba (PPRA) Tahun 2024 RSUP Dr. Sardjito. Yogyakarta : Komite Pengendalian dan Pencegahan Infeksi (PPI) dan Program Pengendalian Resistensi Antimikroba (PPRA), hal. 1-53.
- Anonim (2019). VITEK® 2 GN, in: *Package Insert VITEK® 2 GN*. bioMerieux, Inc., North Carolina, hal 1-24.
- Anonim (2018). VITEK® 2 AST-GN93, in: *Package Insert VITEK® 2*. bioMerieux, Inc., North Carolina, hal.1-17.
- Azargun, R., Gholizadeh, P., Sadeghi, V., Hosainzadegan, H., Tarhriz, V., Memar, M.Y., *et al.* (2020). Molecular mechanisms associated with quinolone resistance in *Enterobacteriaceae*: review and update. *Trans R Soc Trop Med Hyg* 114 (10) : 770–781.
- Bala, R., Singh, V.A., Gupta, N., & Rakshit, P. (2020). Prevalence, multidrug-resistance and risk factors for AmpC β -lactamases producing *Escherichia coli* from hospitalized patients. *J Infect Dev Ctries* 14 : 1466–1469.
- Barua, T., Shariff, M., & Thukral, S.S. (2013). Detection and Characterization of AmpC B-Lactamases in Indian Clinical Isolates of *Escherichia coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca*. *Univers J Microbiol Res* 1 : 15–21.
- Basavaraju, M., & Gunashree, B.S. (2023). *Escherichia coli* : An Overview of Main Characteristics, in: Starčič Erjavec, M. (Ed.), *Escherichia Coli - Old and New Insights*. IntechOpen, hal.1-21.
- Bisacchi, G.S. (2015). Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”: Miniperspective. *J. Med. Chem.* 58 : 4874–4882.
- Bush, K., & Bradford, P.A. (2020). Epidemiology of β -Lactamase-Producing Pathogens. *Clin Microbiol Rev* 33 : 1–37.
- Chakkour, M., Hammoud, Z., Farhat, S., El Roz, A., Ezzeddine, Z., & Ghssein, G. (2024). Overview of *Proteus mirabilis* pathogenicity and virulence. Insights into the role of metals. *Front. Microbiol.* 15 : 1–17.
- Cheng, L., Nelson, B.C., Mehta, M., Seval, N., Park, S., Giddins, M.J., *et al.* (2017). Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment

- of Bloodstream Infections Due to AmpC β -Lactamase-Producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* 61.
- Choi, Y.K., Byeon, E.J., Park, J.J., Lee, J., & Seo, Y.B. (2021). Antibiotic Resistance Patterns of *Enterobacteriaceae* Isolated from Patients with Healthcare-Associated Infections. *Infect Chemother* 53 : 355.
- Collins, V.L., Marchaim, D., Pogue, J.M., Moshos, J., Bheemreddy, S., Sunkara, B., *et al.* (2012). Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* 56 : 2173–2177.
- Correia, S., Poeta, P., Hébraud, M., Capelo, J.L., & Igrejas, G. (2017). Mechanisms of quinolone action and resistance: where do we stand? *J. Med. Microbiol* 66 : 551–559.
- Dalhoff, A. (2012). Global Fluoroquinolone Resistance Epidemiology and Implications for Clinical Use. *Interdiscip Perspect Infect Dis* 2012 : 1–37.
- Datta, P., Gupta, V., Arora, S., Garg, S., & Chander, J. (2014). Epidemiology of Extended-Spectrum β -Lactamase, AmpC, and Carbapenemase Production in *Proteus mirabilis*. *Jpn J Infect Dis* 67 : 44–46.
- Dong, N., Yang, X., Chan, E.W.-C., Zhang, R., & Chen, S. (2022). Klebsiella species: Taxonomy, hypervirulence and multidrug resistance. *eBioMedicine* 79 : 1–11.
- Etemadi, S., Ebrahimzadeh Leylabadlo, H., & Ghotaslou, R. (2020). AmpC β -lactamase among *Enterobacteriaceae*: A new insight. *Gene Rep* 19 : 1–6.
- Fàbrega, A., Madurga, S., Giralt, E., & Vila, J. (2009). Mechanism of action of and resistance to quinolones. *Microb Biotechnol* 2 : 40–61.
- Girlich, D., Bonnin, R.A., Dortet, L., & Naas, T. (2020). Genetics of Acquired Antibiotic Resistance Genes in *Proteus spp.* *Front. Microbiol.* 11 : 1–21.
- Grover, N., Sahni, A.K., & Bhattacharya, S. (2013). Therapeutic challenges of ESBLs and AmpC beta-lactamase producers in a tertiary care center. *Med J Armed Forces India* 69 : 4–10.
- Gunter, S.G., Barber, K.E., Wagner, J.L., & Stover, K.R. (2020). Fluoroquinolone Versus Nonfluoroquinolone Treatment of Bloodstream Infections Caused by Chromosomally Mediated AmpC-Producing *Enterobacteriaceae*. *Antibiotics* 9 : 331.
- Gupta, G., Tak, V., & Mathur, P. (2014). Detection of AmpC β Lactamases in Gram-negative Bacteria. *J Lab Physicians* 6 : 001–006.
- Hall, B.G., & Barlow, M. (2004). Evolution of the serine β -lactamases: past, present and future. *Drug Resist Updat* 7 : 111–123.
- Han, C., Yang, Y., Wang, M., Wang, A., Lu, Q., Xu, X., *et al.* (2010). The prevalence of plasmid-mediated quinolone resistance determinants among clinical isolates of ESBL or AmpC-producing *Escherichia coli* from Chinese pediatric patients. *Microbiol Immunol* 54 : 123–128.
- Harris, P.N.A., & Ferguson, J.K. (2012). Antibiotic therapy for inducible AmpC β -lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? *Int J Antimicrob Agents* 40 : 297–305.

- Helmy, M.M., & Wasfi, R. (2014). Phenotypic and Molecular Characterization of Plasmid Mediated AmpC β -Lactamases among *Escherichia coli*, *Klebsiella* spp., and *Proteus mirabilis* Isolated from Urinary Tract Infections in Egyptian Hospitals. *Biomed Res Int* 2014 : 1–8.
- Hoseinzadeh, M., Sedighi, M., Yahyapour, Y., Javanian, M., Beiranvand, M., Mohammadi, M., *et al.* (2024). Prevalence of plasmid-mediated quinolone resistance genes in extended-spectrum beta-lactamase producing *Klebsiella pneumoniae* isolates in northern Iran. *Heliyon* 10 : e37534.
- Hulley, S.B., Cummings, S.R., Browner, W.S., Grady, D.G., & Newman, T.B. (2007). *Designing Clinical Research*, 4th ed. Lippincott William & Wilkins. Philadelphia, hal. 1-381
- Inamdar, D.P., & Anuradha, B. (2020). Phenotypic methods for detection of Amp C β lactamases in Gram negative clinical isolates of a tertiary care hospital. *IJMR* 7 : 125–129.
- Jacoby, G.A. (2009). AmpC β -Lactamases. *Clin Microbiol Rev* 22 : 161–182.
- Janda, J.M., & Abbott, S.L. (2021). The Changing Face of the Family *Enterobacteriaceae* (Order: “*Enterobacterales*”): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and Disease Syndromes. *Clin Microbiol Rev* 34 : 1–45.
- Jeong, H.S., Bae, I.K., Shin, J.H., Jung, H.J., Kim, S.H., Lee, J.Y., *et al.* (2011). Prevalence of Plasmid-mediated Quinolone Resistance and Its Association with Extended-spectrum Beta-lactamase and AmpC Beta-lactamase in *Enterobacteriaceae*. *Ann Lab Med* 31 : 257–264.
- Lee, C.-H., Lee, Y.-T., Kung, C.-H., Ku, W.-W., Kuo, S.-C., Chen, T.-L., *et al.* (2015). Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β -lactamase-producing *Enterobacteriaceae*. *J Microbiol Immunol Infect* 48 : 269–275.
- Li, Y.Y., Cassidy, F., Salmon, A., Keating, D., Herra, C.M., & Schaffer, K. (2015). Detection and epidemiology of plasmid-mediated AmpC β -lactamase producing *Escherichia coli* in two Irish tertiary care hospitals. *J Glob Antimicrob Resist* 3 : 242–246.
- Luzzaro, F., Brigante, G., D’Andrea, M.M., Pini, B., Giani, T., Mantengoli, E., *et al.* (2009). Spread of multidrug-resistant *Proteus mirabilis* isolates producing an AmpC-type β -lactamase: epidemiology and clinical management. *Int J Antimicrob Agents* 33 : 328–333.
- Lyonga, E.E., Toukam, M., Nkenfou, C., Gonsu, H.K., Assoumou, M.-C.O., Mesembe, M.T., *et al.* (2015). Resistance pattern of *Enterobacteriaceae* isolates from urinary tract infections to selected quinolones in Yaoundé. *Pan Afr Med J* 21.
- MacDougall, C. (2011). Beyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β -Lactamases. *J Pediatr Pharmacol Ther* 16 : 23–30.
- Machuca, J., Agüero, J., Miró, E., Conejo, M.D.C., Oteo, J., Bou, G., *et al.* (2017). Prevalencia en España de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. *Enferm Infecc Microbiol Clin* 35 : 487–492.

- Mahon, C.R., Lehman, D.C., & Louis, S. (2019). Chapter 12: Antibacterial Mechanism of Action and Bacterial Resistance Mechanism, in: Mahon, C.R & Lehman, D.C (Ed.) *Textbook of Diagnostic Microbiology*. Elsevier Saunders, Missouri. hal 247-267.
- Marchisio, M., Porto, A., Joris, R., Rico, M., Baroni, M.R., & Di Conza, J. (2015). Susceptibility to β -lactams and quinolones of *Enterobacteriaceae* isolated from urinary tract infections in outpatients. *Braz. J. Microbiol.* 46 : 1155–1159.
- Mawarti, Y., Dewi, A.D., Wulandari, A., Soetardjo, I.A.E., Muljono, B., Sianipar, O., *et al.* (2024). *ola Mikroba dan Kepekaan Terhadap Antimikroba (Antibiogram) Tahun 2023*. Komite Pencegahan dan Pengendahlilan Infeksi Program Pengendalian Resistensi Antimikroba RSUP Dr. Sardjito Yogyakarta, Yogyakarta, hal.1-274.
- Meini, S., Tascini, C., Cei, M., Sozio, E., & Rossolini, G.M. (2019). AmpC β -lactamase-producing *Enterobacteriales*: what a clinician should know. *Infection* 47 : 363–375.
- Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017). *Klebsiella pneumoniae*: a major worldwide source and shuttle for antibiotic resistance. *FEMS Microbiol Rev* 41 : 252–275.
- Nordmann, P., Dortet, L., & Poirel, L. (2012). Carbapenem resistance in *Enterobacteriaceae*: here is the storm! *Trends Mol Med* 18 : 263–272.
- Oliveira, J., & Reygaert, W.C. (2025). Gram-Negative Bacteria, in: *StatPearls*. Treasure Island (FL) : StatPearls Publishing.
- Paczosa, M.K., & Meccas, J. (2016). *Klebsiella pneumoniae*: Going on the Offense with a Strong Defense. *Microbiol Mol Biol Rev* 80 : 629–661.
- Paterson, D.L. (2006). Resistance in Gram-Negative Bacteria: *Enterobacteriaceae*. *Am J Med* 119 : S20–S28.
- Permatasari, D.A., Witaningrum, A.M., Wibisono, F.J., & Effendi, M.H. (2020). Detection and prevalence of multidrug-resistant *Klebsiella pneumoniae* strains isolated from poultry farms in Blitar, Indonesia. *Biodiversitas* 21 : 4642–4647.
- Popiołek, Ł., & Gawrońska-Grzywacz, M. (2015). The Impact of Modifying the Chemical Structure of Nalidixic Acid on the Antimicrobial Activity of Its Derivatives: A Review. *IRJPAC* 7 : 191–202.
- Priyaka, I.G.N.K., Tarini, N.M.A., & Fatmawati, N.N.D. (2019). Deteksi Molekuler Gen AmpC pada Isolat Klinis *Klebsiella pneumoniae* Penghasil ESBL di RSUP Sanglah Denpasar. *Jurnal Medika Udayana* 8 : 1–5.
- Riedel, S., Hobden, J.A, Miller, S., Morse, S.A., Mietzner, T.A., Detrick, B., *et al.* (2019). Enteric Gram-negative Rods (*Enterobacteriaceae*), in: Riedel, S., Morse, S.A., Mietzner, S.A., Miller, S. (Ed.) *Jawetz, Melnick, & Adelberg's Medical Microbiology*. Mc Graw Hill Lange. New York, hal. 235-252.
- Rodríguez-Guerrero, E., Callejas-Rodelas, J.C., Navarro-Marí, J.M., & Gutiérrez-Fernández, J. (2022). Systematic Review of Plasmid AmpC Type Resistances in *Escherichia coli* and *Klebsiella pneumoniae* and Preliminary Proposal of a Simplified Screening Method for ampC. *Microorganisms* 10 : 611.

- Rolston, K.V.I. (2017). Infections in Cancer Patients with Solid Tumors: A Review. *Infect Dis Ther* 6 : 69–83.
- Ruh, E., Zakka, J., Hoti, K., Fekrat, A., Guler, E., Gazi, U., *et al.* (2019). Extended-spectrum β -lactamase, plasmid-mediated AmpC β -lactamase, fluoroquinolone resistance, and decreased susceptibility to carbapenems in *Enterobacteriaceae*: fecal carriage rates and associated risk factors in the community of Northern Cyprus. *Antimicrob Resist Infect Control* 8 : 98.
- Shagufta, R., Fomda, B., Gulnaz, B., Lubna, S., Jan, A., Mohd, S., *et al.* (2017). Prevalence of AmpC Beta-lactamase in Gram Negative Bacilli by Different Phenotypic Methods in a Tertiary Care Institute in Kashmir. *Br J Med Res* 19 : 1–9.
- Shariati, A., Arshadi, M., Khosrojerdi, M.A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., *et al.* (2022). The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. *Front. Public Health* 10 : 1025633.
- Sood, R., Walo, C., Burton, R., Khalife, M., Dicko, A., & Mangana, F. (2023). Spontaneous nosocomial *Proteus mirabilis* meningitis in a Human Immunodeficiency Virus (HIV)-infected adult patient: a case report. *J Med Case Reports* 17 : 1–7.
- Tamma, P.D., Doi, Y., Bonomo, R.A., Johnson, J.K., Simner, P.J., Antibacterial Resistance Leadership Group, *et al.* (2019). A Primer on AmpC β -Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. *Clin Infect Dis* 69 : 1446–1455.
- Tang, K., & Zhao, H. (2023). Quinolone Antibiotics: Resistance and Therapy. *IDR* Volume 16 : 811–820.
- Tebano, G., Zaghi, I., Cricca, M., & Cristini, F. (2024). Antibiotic Treatment of Infections Caused by AmpC-Producing *Enterobacterales*. *Pharmacy* 12 : 1–17.
- Tekele, S.G., Teklu, D.S., Tullu, K.D., Birru, S.K., & Legese, M.H. (2020). Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia. *PLOS ONE* 15 : e0241984.
- Tewari, R., Mitra, S.D., Ganaie, F., Venugopal, N., Das, S., Shome, R., *et al.* (2018). Prevalence of extended spectrum β -lactamase, AmpC β -lactamase and metallo β -lactamase mediated resistance in *Escherichia coli* from diagnostic and tertiary healthcare centers in south Bangalore, India. *Int J Res Med Sci* 6 : 1308–1313.
- Tille, P.M. (2017). *Enterobacteriaceae*, in: Tille, P.M (Ed.) *Bailey & Scott's Diagnostic Microbiology*. Elsevier , St. Louis Missouri, hal. 239–356.
- Toleman, M.A., Bennett, P.M., & Walsh, T.R. (2006). IS CR Elements: Novel Gene-Capturing Systems of the 21st Century? *Microbiol Mol Biol Rev* 70 : 296–316.
- Varughese, L.R., Rajpoot, M., Goyal, S., Mehra, R., Chhokar, V., & Beniwal, V. (2018). Analytical profiling of mutations in quinolone resistance determining region of gyrA gene among UPEC. *PLOS ONE* 13 : e0190729.

- Woerther, P.-L., Burdet, C., Chachaty, E., & Andremont, A. (2013). Trends in Human Fecal Carriage of Extended-Spectrum β -Lactamases in the Community: Toward the Globalization of CTX-M. *Clin Microbiol Rev* 26 : 744–758.
- Woodford, N., Turton, J.F., & Livermore, D.M. (2011). Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol Rev* 35 : 736–755.
- Yanat, B., Rodríguez-Martínez, J.-M., & Touati, A. (2017). Plasmid-mediated quinolone resistance in *Enterobacteriaceae*: a systematic review with a focus on Mediterranean countries. *Eur J Clin Microbiol Infect Dis* 36 : 421–435.
- Yong, D., Lim, Y.S., Roh, K.H., Choi, Y.S., Park, D.-Y., Yum, J.H., *et al.* (2006). The first detection of CTX-M-14 extended-spectrum β -lactamase among diverse β -lactamase-producing *Proteus mirabilis* clinical isolates. *Diagn Microbiol Infect Dis* 54 : 237–239.
- Yusuf, K., Sampath, V., & Umar, S. (2023). Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients. *IJMS* 24 : 3110.
- Zamorano, L., Miró, E., Juan, C., Gómez, L., Bou, G., González-López, J.J., *et al.* (2015). Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC β -Lactamases or Carbapenemases from *Enterobacteriaceae*: Findings from a Multicenter Study in Spain. *Antimicrob Agents Chemother* 59 : 5260–5266.
- Zhou, Q., Tang, M., Zhang, X., Lu, J., Tang, X., & Gao, Y. (2022). Detection of AmpC β -lactamases in gram-negative bacteria. *Heliyon* 8 : 1–7.